Current perspectives on use of anti-vascular endothelial growth factor agents for retinal disorders
Open Access
- 1 January 2021
- journal article
- editorial
- Published by Medknow in Indian Journal of Ophthalmology
- Vol. 69 (2), 209-210
- https://doi.org/10.4103/ijo.ijo_72_21
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Immediate onset of sterile endophthalmitis with hypopyon after intravitreal Brolucizumab in a case of polypoidal choroidal vasculopathyIndian Journal of Ophthalmology, 2021
- Clinical efficacy and safety of Razumab® (CESAR) study: Our experience with the world's first biosimilar RanibizumabIndian Journal of Ophthalmology, 2021
- Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF SurveyIndian Journal of Ophthalmology, 2021
- Occlusive Retinal Vasculitis Following Intravitreal BrolucizumabJournal of Vitreoretinal Diseases, 2020
- Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of BrolucizumabOphthalmology, 2020
- HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular DegenerationOphthalmology, 2020
- Aflibercept, bevacizumab or ranibizumab for diabetic macular oedemaCurrent Opinion in Opthalmology, 2017
- Intravitreal Ziv-Aflibercept: Clinical Effects and Economic ImpactAsia-Pacific Journal of Ophthalmology, 2017
- Counterfeit Avastin in India: Punish the Criminals, Not the PatientsAmerican Journal of Ophthalmology, 2016
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2011